Market Overview

UPDATE: Jefferies Raises PT on Pfizer on Attractive Valuation

Share:
Related PFE
Dow 30 Stock Roundup: Boeing Bags Big Orders at Paris Air Show; Wal-Mart to Buy Bonobos
S&P Companies Spending 18% Less On Buybacks, But What Does It Mean For Investors?
Biotech Stock With 497% Growth, Positive Trial Results Nears Buy Zone (Investor's Business Daily)

In a report published Wednesday, Jefferies analyst Jeffrey Holford reiterated a Buy rating on Pfizer (NYSE: PFE), and raised the price target from $31.00 to $33.00.

In the report, Holford noted, “We remain positive on Pharmaceuticals and see valuation as attractive for most stocks. Our Top Pick in the US is AbbVie, with Novartis being our most preferred name in Europe. Sanofi, Roche and Pfizer remain high conviction Buy ratings. We point to Eli Lilly and GlaxoSmithKline as least preferred names.”

Pfizer closed on Tuesday at $29.11.

Latest Ratings for PFE

DateFirmActionFromTo
May 2017CitigroupDowngradesNeutralSell
Dec 2016GuggenheimInitiates Coverage OnNeutral
Nov 2016BarclaysUpgradesEqual-WeightOverweight

View More Analyst Ratings for PFE
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color Price Target Analyst Ratings

 

Related Articles (PFE)

View Comments and Join the Discussion!